Tildrakizumab for the Treatment of Moderate-to-Severe Psoriasis: Results from 52 Weeks Real-Life Retrospective Study

Tildrakizumab for the Treatment of Moderate-to-Severe Psoriasis: Results from 52 Weeks Real-Life Retrospective Study

Angelo Ruggiero, Gabriella Fabbrocicni, Sara Cacciapuoti, Luca Potestio, Lucia Gallo, Matteo Megna Section of Dermatology, Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, ItalyCorrespondence: Angelo Ruggiero, Section of Dermatology, Department of Clinical Medic...

Celý popis

Podrobná bibliografie
Hlavní autoři: Ruggiero A, Fabbrocicni G, Cacciapuoti S, Potestio L, Gallo L, Megna M
Médium: Článek
Jazyk:English
Vydáno: Dove Medical Press 2023-02-01
Edice:Clinical, Cosmetic and Investigational Dermatology
Témata:
guselkumab
risankizumab
tildrakizumab
real world practice
psoriasis
anti-il-23
biologics.
On-line přístup:https://www.dovepress.com/tildrakizumab-for-the-treatment-of-moderate-to-severe-psoriasis-result-peer-reviewed-fulltext-article-CCID

Internet

https://www.dovepress.com/tildrakizumab-for-the-treatment-of-moderate-to-severe-psoriasis-result-peer-reviewed-fulltext-article-CCID

Podobné jednotky